



AUREALIS THERAPEUTICS

AUREALIS THERAPEUTICS  
MULTI-THERAPY BACTERIAL VECTOR PLATFORM FOR WOUNDS AND CANCER

Juha Yrjänheikki, CEO

SWISS BIOTECH DAY 2023

# THE NEED: MASSIVE UNMET NEED AND MARKET OPPORTUNITY



**4 Mn & 6.5 Mn**  
Annual Incidence  
EU & US



**30%**  
2 year mortality



**30%**  
Total healthcare  
costs (>€100Bn)



**1 amputation**  
Every 30 seconds



**25-50%**  
Hospital beds  
occupied



**12%**  
Rising prevalence  
per year




**313,959\***  
Women diagnosed  
Each year



**207,252\***  
Women die each  
year



**45%**  
Overall 5 year  
survival



**2M**  
Prevalence



**<20%**  
Stage 3 and 4  
5 year survival

## CHRONIC WOUNDS

\$100Bn cost to the society  
\$15Bn global market

**Chronic Wounds:**  
DFU (diabetic foot ulcer)  
VLU (venous leg ulcer)  
PU (pressure ulcer)

## OVARIAN CANCER

Deadly disease  
Over \$5Bn global market

Sources: International Diabetes Federation, Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis (Ann Med. 2017 Mar), \*WHO 2020 data



AUREALIS  
THERAPEUTICS

MULTI-TARGET CELL & GENE THERAPIES  
FOR UNMET MEDICAL NEEDS


# THE PROBLEM:

- CURING MULTI-FACTORIAL DISEASES REQUIRE MULTITARGETING
- CURRENT TREATMENTS DO NOT ENABLE IT



# THE SOLUTION: AUREALIS THERAPEUTICS 4-IN-1 PLATFORM

## CELL & GENE PLATFORM ENABLING MULTITARGET THERAPY AS ONE PRODUCT



GRAS\* PROBIOTIC LACTOCOCCUS ACTING AS MILLIONS OF NANOSCALE BIOREACTORS IN THE BODY ENGINEERED TO PRODUCE AND SECRETE THREE THERAPEUTIC HUMAN PROTEINS

\*GRAS (FDA): GENERALLY RECOGNIZED AS SAFE








AUREALIS  
THERAPEUTICS

MULTI-TARGET CELL & GENE THERAPIES  
FOR UNMET MEDICAL NEEDS


# MODULAR MULTI-THERAPY BACTERIAL VECTOR PLATFORM

## GENE ENCODING OPTIONS



-  INTERLEUKINS
-  OTHER CYTOKINES
-  GROWTH FACTORS
-  ENZYMES, ScFv...

## CONSTRUCTS



## THERAPY AREAS

CHRONIC WOUNDS

ONCOLOGY

INFLAMMATION

OTHER






# AUP-16




## THE 4-IN-1 SOLUTION FOR CHRONIC WOUNDS

# AUP-55

## THE 4-IN-1 SOLUTION FOR OVARIAN CANCER & PERITONEAL CARCINOMATOSIS



Applied topically

-  INTERLEUKINS
-  OTHER CYTOKINES
-  GROWTH FACTORS

Injected intratumorally



AUREALIS  
THERAPEUTICS

MULTI-TARGET CELL & GENE THERAPIES  
FOR UNMET MEDICAL NEEDS

# PRODUCT PORTFOLIO

## MULTI-TARGET CELL & GENE THERAPIES FOR UNMET MEDICAL NEEDS

Modality	Product	Indication	Discovery	In vivo POC	GLP S&T CMC	IND/CTA	Phase 1	Phase 2	Phase 3	NDA/MAA
Chronic Wounds	AUP-16	Diabetic Foot Ulcer	[Progress bar: Discovery to Phase 1]							
	AUP-16	Venous Leg Ulcer	[Progress bar: Discovery to Phase 1]							
	AUP-16	Pressure Ulcer	[Progress bar: Discovery to Phase 1]							
Oncology	AUP-55	Ovarian Cancer	[Progress bar: Discovery to In vivo POC]							
	AUP-55	Peritoneal Carcinomatosis	[Progress bar: Discovery to In vivo POC]							
	AUP-65	Third Cancer Indication	[Progress bar: Discovery to In vivo POC]							
Inflammation	AUP-18	Dermatology (undisclosed)	[Progress bar: Discovery to In vivo POC]							
	AUP-20	Metabolic (undisclosed)	[Progress bar: Discovery to In vivo POC]							

\*Partner customized new construct/product with desired 2-3 human therapeutic proteins can be created in 6 weeks.



# HOW WE DIFFERENTIATE FROM COMPETITION

	Aurealis Therapeutics platform	Non-pathogenic bacteria-based	Pathogenic bacteria-based	Viral vectors	Human cell and tissue therapies
Enables 4-in-1 targeting	✓	✗	✗	✗	✗
Non-pathogenic	✓	✓	✗	✗	✓
Controllable when administered	✓	✓	✓	✗	✗
Cost of goods and manufacturing, and scalability	✓	✓	✓	✗	✗
Easy to use	✓	✓	✓	✓	✗

Cell and gene therapy **technology platform comparison**. Separate competition analysis in each indication.





## CONTACTS:

CEO Juha Yrjänheikki, [juha@aurealistherapeutics.com](mailto:juha@aurealistherapeutics.com)

COO Laurent Décory, [laurent@aurealistherapeutics.com](mailto:laurent@aurealistherapeutics.com)



**AUREALIS THERAPEUTICS**

MULTI-TARGET CELL & GENE THERAPIES  
FOR UNMET MEDICAL NEEDS

